الفهرس 
CARDIOVASCULAR DISEASE AND RISK FACTORS INOnly 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with all forms of chronic kidney disease (CKD).
Cardiovascular disease accounts for 40% to 50% of deaths in dialysis populations. Overall, the risk of cardiac mortality is 10-fold to 20-fold greater in dialysis patients than in age and sex-matched controls without chronic kidney disease.
Dyslipidaemia is a consequence of renal disease, wherein hepatic synthesis of lipoproteins is increased and clearance decreased. The resulting lipoprotein phenotype is highly atherogenic and significantly increases the cardiovascular risk of the patients. Chronic renal disease is accompanied by characteristic abnormalities of lipid metabolism,which appear as a consequence of renal insufficiency and are reflected in an altered apolipoprotein profile as well as elevated plasma lipid levels. Experimental and clinical studies have suggested a correlation between the progression of renal disease and dyslipidemia. High cholesterol and triglyceride plasma levels have been demonstrated to be independent risk factors for progression of renal disease in humans.
Recombinant human erythropoietin (rHuEPO) a novel and a triumph of modern medicine in the field of nephrology, allowing: avoidance of blood transfusion, reduction in the risk of sensitization, prevention of iron overload and improved exercise tolerance, cognitive capacity, sexual function and quality of life. The treatment of anaemia was deeply transformed.
Long-term rHuEPO treatment may be associated with an improvement in the lipid profile. So that, the high incidence of cardiovascular disease in hemodialysis (HD) patients might be reduced with rHuEPO therapy.
The aim of this study was to study the possible effect of recombinant human erythropoietin (rHuEPO) therapy on lipogram in chronic haemodialysis patients.